Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:PRTK
- CUSIP: 89354M10
- Web: www.paratekpharma.com
Capitalization:- Market Cap: $688.48 million
- Outstanding Shares: 27,761,000
Average Prices:- 50 Day Moving Avg: $23.26
- 200 Day Moving Avg: $21.71
- 52 Week Range: $9.80 - $29.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.46
- P/E Growth: -0.03
Sales & Book Value:- Annual Revenue: $7.56 million
- Price / Sales: 90.70
- Book Value: $4.11 per share
- Price / Book: 6.01
Profitability:- EBIDTA: ($90,380,000.00)
- Return on Equity: -107.52%
- Return on Assets: -64.00%
Debt:- Debt-to-Equity Ratio: 0.43%
- Current Ratio: 11.88%
- Quick Ratio: 11.88%
Misc:- Average Volume: 774,208 shs.
- Beta: 0.75
- Short Ratio: 3.22
Frequently Asked Questions for Paratek Pharmaceuticals (NASDAQ:PRTK)
What is Paratek Pharmaceuticals' stock symbol?
Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
How were Paratek Pharmaceuticals' earnings last quarter?
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) released its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.89) by $0.25. The business earned $7.51 million during the quarter, compared to analysts' expectations of $7.50 million. View Paratek Pharmaceuticals' Earnings History.
Where is Paratek Pharmaceuticals' stock going? Where will Paratek Pharmaceuticals' stock price be in 2017?
8 equities research analysts have issued 12-month price objectives for Paratek Pharmaceuticals' stock. Their forecasts range from $23.00 to $56.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $39.50 in the next twelve months. View Analyst Ratings for Paratek Pharmaceuticals.
What are analysts saying about Paratek Pharmaceuticals stock?
Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "There has been a lot of interest this morning in headlines stating that PRTK is considering all of its strategic options including a sale of the company. We have always believed that PRTK is a very interesting asset in a consolidating space where many antibiotic companies have been taken out. Please see our previously published research on PRTK for more details on our thoughts here. With positive Phase 3 data, PRTK is at the inflection point where potential acquirors would take a look since the asset has been de-risked." (8/23/2017)
- 2. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (8/8/2017)
- 3. Robert W. Baird analysts commented, "Though sarecycline is not a key driver, it provides a potential source of non-dilutive financing and further validates Paratek's ability to develop a once daily, well tolerated, tetracycline-derived antibiotic. Looking ahead, we expect continued momentum with focus on key upcoming data readouts from two Phase 3 studies of omadacycline in 2Q17, supporting filing in 1H18, and we reiterate our Outperform rating." (3/27/2017)
Who are some of Paratek Pharmaceuticals' key competitors?
Some companies that are related to Paratek Pharmaceuticals include Lexicon Pharmaceuticals (LXRX), Epizyme (EPZM), Dynavax Technologies Corporation (DVAX), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dermira (DERM), Acorda Therapeutics (ACOR), Xencor (XNCR), NeuroDerm (NDRM), Five Prime Therapeutics (FPRX), Omeros Corporation (OMER), Athenex (ATNX), REGENXBIO (RGNX), Ascendis Pharma A/S (ASND), Amarin Corporation PLC (AMRN), Retrophin (RTRX), ZIOPHARM Oncology (ZIOP) and Flexion Therapeutics (FLXN).
Who are Paratek Pharmaceuticals' key executives?
Paratek Pharmaceuticals' management team includes the folowing people:
- Michael F. Bigham CPA, Chairman of the Board, Chief Executive Officer
- Evan Loh M.D., President, Chief Operating Officer, Chief Medical Officer, Director
- Douglas W Pagan, Chief Financial Officer
- William M. Haskel, Senior Vice President, General Counsel, Corporate Secretary
- Regina D. Paglia, Senior Vice President - Human Resources
- Jeanne Jew, Senior Vice President - Business Development
- Evan Tzanis, Senior Vice President - Clinical Development and Clinical Operations
- Rajesh Padmanabhan, Vice President - Information Technology
- Stephen Villano M.D., Vice President - Clinical and Medical Affairs
- Adam Woodrow, Vice President and Chief Commercial Officer
Who owns Paratek Pharmaceuticals stock?
Paratek Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Omega Fund Management LLC (9.46%), FMR LLC (5.30%), Vanguard Group Inc. (3.14%), State Street Corp (2.22%), Renaissance Technologies LLC (2.16%) and Tekla Capital Management LLC (1.92%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Fund Iv LP Omega and Michael Bigham. View Institutional Ownership Trends for Paratek Pharmaceuticals.
Who sold Paratek Pharmaceuticals stock? Who is selling Paratek Pharmaceuticals stock?
Paratek Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Tekla Capital Management LLC, Nexthera Capital LP, Balyasny Asset Management LLC, Boston Partners, Essex Investment Management Co. LLC, Ardsley Advisory Partners and Victory Capital Management Inc.. Company insiders that have sold Paratek Pharmaceuticals stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.
Who bought Paratek Pharmaceuticals stock? Who is buying Paratek Pharmaceuticals stock?
Paratek Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Pictet Asset Management Ltd., State Street Corp, Numeric Investors LLC, Franklin Resources Inc., JPMorgan Chase & Co., Renaissance Technologies LLC and Nicholas Investment Partners LP. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Evan Loh, Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.
How do I buy Paratek Pharmaceuticals stock?
Shares of Paratek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Paratek Pharmaceuticals' stock price today?
One share of Paratek Pharmaceuticals stock can currently be purchased for approximately $24.70.
MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Paratek Pharmaceuticals (NASDAQ:PRTK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 3.13) |
| Consensus Price Target: | $39.50 (59.92% upside) |
Analysts' Ratings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/21/2017 | Cantor Fitzgerald | Reiterated Rating | Buy | $50.00 | Low |  |
| 8/24/2017 | Raymond James Financial, Inc. | Reiterated Rating | Strong-Buy | $36.00 | Medium | |
| 7/18/2017 | HC Wainwright | Boost Price Target | Positive -> Buy | $36.00 -> $43.00 | High | |
| 4/4/2017 | Guggenheim | Set Price Target | Buy | $38.00 | Medium | |
| 4/4/2017 | BTIG Research | Boost Price Target | Buy | $47.00 -> $56.00 | Medium | |
| 4/4/2017 | Robert W. Baird | Reiterated Rating | Outperform | $40.00 | Medium | |
| 4/3/2017 | Wedbush | Reiterated Rating | Outperform -> Outperform | $30.00 | High | |
| 11/3/2016 | Leerink Swann | Reiterated Rating | Buy | $23.00 | N/A | |
| 6/17/2016 | Ladenburg Thalmann Financial Services | Boost Price Target | Buy | $46.00 -> $52.00 | N/A | |
(Data available from 9/23/2015 forward)
Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)Earnings History by Quarter for Paratek Pharmaceuticals (NASDAQ PRTK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | Q2 2017 | ($0.89) | ($0.64) | $7.50 million | $7.51 million | View | Listen | |
| 5/4/2017 | Q1 2017 | ($1.20) | ($1.14) | | $0.02 million | View | Listen | |
| 3/2/2017 | Q4 2016 | ($1.33) | ($1.17) | | $0.03 million | View | Listen | |
| 11/2/2016 | | ($1.38) | ($1.04) | | | View | N/A | |
| 5/2/2016 | | ($1.25) | ($1.77) | | | View | N/A | |
| 2/23/2016 | Q4 | ($1.18) | ($1.20) | | | View | Listen | |
| 11/12/2015 | Q315 | ($0.91) | ($1.33) | | | View | Listen | |
| 8/5/2015 | Q215 | ($0.75) | ($0.94) | $3.62 billion | | View | N/A | |
| 4/2/2015 | Q1 | ($2.16) | ($0.74) | $0.13 million | $4.00 million | View | N/A | |
| 5/5/2014 | | ($0.18) | ($0.15) | | $0.42 million | View | N/A | |
| 3/13/2014 | Q413 | ($0.21) | ($0.29) | $0.50 million | $0.32 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.42) | ($0.56) | | | View | N/A | |
| 11/12/2012 | Q312 | $0.06 | $0.25 | $8.37 million | $10.44 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)2017 EPS Consensus Estimate: ($3.64)
2018 EPS Consensus Estimate: ($2.96)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($1.15) | ($1.15) | ($1.15) |
| Q2 2017 | 1 | ($0.79) | ($0.79) | ($0.79) |
| Q3 2017 | 2 | ($0.92) | ($0.87) | ($0.90) |
| Q4 2017 | 2 | ($0.94) | ($0.67) | ($0.81) |
| Q1 2018 | 1 | ($0.86) | ($0.86) | ($0.86) |
| Q2 2018 | 1 | ($0.89) | ($0.89) | ($0.89) |
| Q3 2018 | 1 | ($0.48) | ($0.48) | ($0.48) |
| Q4 2018 | 1 | ($0.73) | ($0.73) | ($0.73) |
(Data provided by Zacks Investment Research)
Dividend History by Quarter for Paratek Pharmaceuticals (NASDAQ PRTK)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/14/2014 | special | $1.33 | | 6/4/2014 | 5/26/2014 | 6/3/2014 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Paratek Pharmaceuticals (NASDAQ:PRTK)Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 82.33%
Insider Trades by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/5/2017 | Adam Woodrow | VP | Sell | 3,800 | $23.58 | $89,604.00 | |
| 7/5/2017 | Douglas W Pagan | CFO | Sell | 4,139 | $23.58 | $97,597.62 | |
| 7/5/2017 | Evan Loh | COO | Sell | 4,351 | $23.58 | $102,596.58 | |
| 7/5/2017 | Michael Bigham | Chairman | Sell | 5,075 | $23.58 | $119,668.50 | |
| 6/19/2017 | Douglas W Pagan | CFO | Sell | 4,595 | $25.00 | $114,875.00 | |
| 2/6/2017 | Douglas W Pagan | CFO | Sell | 3,405 | $15.09 | $51,381.45 | |
| 2/6/2017 | Evan Loh | COO | Sell | 3,106 | $15.09 | $46,869.54 | |
| 2/6/2017 | Michael Bigham | Chairman | Sell | 5,000 | $15.09 | $75,450.00 | |
| 6/27/2016 | Fund Iv L.P. Omega | Major Shareholder | Buy | 461,538 | $13.00 | $5,999,994.00 | |
| 6/23/2016 | Michael Bigham | CEO | Buy | 20,000 | $13.45 | $269,000.00 | |
| 12/11/2015 | Evan Loh | CMO | Buy | 2,300 | $16.87 | $38,801.00 | |
| 5/29/2015 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 20,580 | $30.75 | $632,835.00 | |
| 12/13/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 1,470 | $3.54 | $5,203.80 | |
| 12/11/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 10,490 | $3.55 | $37,239.50 | |
| 12/6/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 8,710 | $3.54 | $30,833.40 | |
| 12/4/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 7,120 | $3.50 | $24,920.00 | |
| 11/20/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 10,040 | $3.57 | $35,842.80 | |
| 11/12/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 7,190 | $3.53 | $25,380.70 | |
| 11/7/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 4,960 | $3.61 | $17,905.60 | |
| 10/30/2013 | Roumell Asset Management, Llc | Major Shareholder | Sell | 7,020 | $3.69 | $25,903.80 | |
(Data available from 1/1/2013 forward)
Headline Trends for Paratek Pharmaceuticals (NASDAQ:PRTK)
Latest Headlines for Paratek Pharmaceuticals (NASDAQ:PRTK)
| Source: |
|
| Date | Headline |
|---|
 | Paratek's omadacycline granted additional QIDP status in US - Seeking Alpha
seekingalpha.com - September 23 at 12:38 AM |
 | Paratek Pharmaceuticals, Inc. (PRTK) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - September 22 at 3:50 PM |
 | Omadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract Infections
finance.yahoo.com - September 22 at 2:24 PM |
| Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017
finance.yahoo.com - September 20 at 7:57 AM |
| Brokerages Expect Paratek Pharmaceuticals, Inc. (PRTK) Will Announce Earnings of -$0.93 Per Share
www.americanbankingnews.com - September 17 at 2:28 AM |
| Paratek Pharmaceuticals (PRTK) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 8:00 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 5 at 6:50 AM |
 | Paratek Announces Inducement Grants under NASDAQ Listing Rule ... - GlobeNewswire (press release)
globenewswire.com - September 2 at 7:44 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Downgraded by BidaskClub
www.americanbankingnews.com - August 28 at 7:28 PM |
| Here's Why Paratek Pharmaceuticals Soared as Much as 37% Today
finance.yahoo.com - August 24 at 11:23 AM |
| Today's Research Reports on Stocks to Watch: Paratek Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc.
finance.yahoo.com - August 24 at 11:23 AM |
| Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PRTK-US : August 24, 2017
finance.yahoo.com - August 24 at 11:23 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Catches Eye: Stock Up 27.3%
finance.yahoo.com - August 24 at 11:23 AM |
| Paratek Pharmaceuticals' (PRTK) Strong-Buy Rating Reiterated at Raymond James Financial, Inc.
www.americanbankingnews.com - August 24 at 10:34 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Given Buy Rating at Cantor Fitzgerald
www.americanbankingnews.com - August 23 at 10:54 AM |
| Paratek Pharmaceuticals, Inc. to Present at Upcoming Investor ... - GlobeNewswire (press release)
globenewswire.com - August 23 at 1:59 AM |
| Paratek Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
finance.yahoo.com - August 22 at 3:55 PM |
| Paratek Pharmaceuticals (PRTK) Presents At Wedbush PacGrow Healthcare Conference - Slideshow
seekingalpha.com - August 17 at 7:03 AM |
| Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 11 at 3:24 PM |
| Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Earns "Overweight" Rating from Cantor Fitzgerald
www.americanbankingnews.com - August 10 at 12:46 PM |
| Brokers Offer Predictions for Paratek Pharmaceuticals, Inc.'s FY2017 Earnings (NASDAQ:PRTK)
www.americanbankingnews.com - August 10 at 10:42 AM |
| Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PRTK-US : August 9, 2017
finance.yahoo.com - August 10 at 7:02 AM |
| Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - August 9 at 6:33 AM |
| Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 9 at 6:33 AM |
| Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - August 8 at 8:08 AM |
 | Paratek Pharmaceuticals (PRTK) Gains Tied to Amendment to Change of Control Policy - StreetInsider.com
www.streetinsider.com - August 8 at 6:22 AM |
| Paratek Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($0.87) Per Share, Wedbush Forecasts (NASDAQ:PRTK)
www.americanbankingnews.com - August 7 at 7:34 AM |
| FY2017 Earnings Estimate for Paratek Pharmaceuticals, Inc. (PRTK) Issued By Gabelli
www.americanbankingnews.com - August 7 at 7:06 AM |
| Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Upgraded at Zacks Investment Research
www.americanbankingnews.com - August 6 at 8:12 AM |
| BidaskClub Lowers Paratek Pharmaceuticals, Inc. (PRTK) to Hold
www.americanbankingnews.com - August 4 at 9:20 PM |
| Brokers Set Expectations for Paratek Pharmaceuticals, Inc.'s Q3 2017 Earnings (NASDAQ:PRTK)
www.americanbankingnews.com - August 4 at 7:22 AM |
| Paratek Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PRTK) : August 4, 2017
finance.yahoo.com - August 4 at 7:13 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Announces Quarterly Earnings Results, Beats Estimates By $0.25 EPS
www.americanbankingnews.com - August 3 at 2:52 PM |
| Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update
finance.yahoo.com - August 3 at 7:06 AM |
| Edited Transcript of PRTK earnings conference call or presentation 2-Aug-17 12:30pm GMT
finance.yahoo.com - August 3 at 7:06 AM |
| Paratek reports 2Q loss
finance.yahoo.com - August 3 at 7:06 AM |
| Investor Network: Paratek Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - August 2 at 6:50 AM |
| Investor Network: Paratek Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - August 2 at 6:50 AM |
| Paratek Puts Skin In The Infection Game - Seeking Alpha
seekingalpha.com - July 24 at 4:22 PM |
| Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Expected to Announce Earnings of -$0.89 Per Share
www.americanbankingnews.com - July 21 at 10:18 PM |
 | Breakfast Technical Briefing on Biotech Stocks -- Aurinia Pharma, Esperion Therapeutics, Paratek Pharma, and Verastem
www.prnewswire.com - July 21 at 6:23 AM |
| Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PRTK-US : July 20, 2017
finance.yahoo.com - July 21 at 6:23 AM |
| Paratek Antibiotic Candidate's Phase III Data Favorable
finance.yahoo.com - July 20 at 6:14 AM |
| Paratek Pharmaceuticals to Report Second Quarter 2017 Financial Results and Provide Update on Clinical Progress on August 2, 2017
finance.yahoo.com - July 20 at 6:14 AM |
| Paratek Pharmaceuticals (PRTK) Says Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and ... - StreetInsider.com
www.streetinsider.com - July 18 at 7:32 AM |
| Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections
finance.yahoo.com - July 18 at 7:31 AM |
| Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - July 17 at 7:15 PM |
| Paratek Pharmaceuticals, Inc. (PRTK) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 10:49 AM |
| Is the Options Market Predicting a Spike in Paratek (PRTK) Stock?
finance.yahoo.com - July 12 at 7:09 AM |
 | Notable Monday Option Activity: NEWR, STT, PRTK - Nasdaq
www.nasdaq.com - July 11 at 6:47 AM |
Paratek Pharmaceuticals (PRTK) Chart for Saturday, September, 23, 2017
